Research Support, Non-U.S. Gov'ts
- Preliminary Study about Sublingual Administration of Bacteria-expressed Pandemic H1N1 Influenza Vaccine in Miniature Pigs
-
Hyekwon Kim , Jeong-Ki Kim , Hohyun Song , Jungah Choi , Byoungshik Shim , Bokyu Kang , Hyoungjoon Moon , Minjoo Yeom , Sang-Hyun Kim , Daesub Song , Manki Song
-
J. Microbiol. 2014;52(9):794-800. Published online July 30, 2014
-
DOI: https://doi.org/10.1007/s12275-014-4289-4
-
-
15
View
-
0
Download
-
4
Citations
-
Abstract
- Sublingual (SL) administration of influenza vaccine would be non-invasive and effective way to give human populations protective immunity against the virus, especially when pandemic influenza outbreaks. In this study, the efficacy of pandemic influenza virus-based subunit vaccines was tested after sublingual (SL) adjuvant administration in pigs. Eight specific pathogen-free Yucatan pigs were divided into 4 groups: nonvaccinated but challenged (A) and vaccinated and challenged (B, C, and D). The vaccinated groups were subdivided by vaccine type and inoculation route: SL subunit vaccine (hemagglutinin antigen 1 [HA1] + wild-type cholera toxin [wtCT], B); IM subunit vaccine (HA1 + aluminum hydroxide, C); and IM inactivated vaccine (+ aluminum hydroxide, D). The vaccines were administered twice at a 2-week interval. All pigs were challenged with pandemic influenza virus (A/swine/ GCVP-KS01/2009 [H1N1]) and monitored for clinical signs, serology, viral shedding, and histopathology. After vaccination, hemagglutination inhibition titre was higher in group D (320) than in the other vaccinated groups (40–80) at the time of challenge. The mobility and feed intake were reduced in group C. Both viral shedding and histopathological lesions were reduced in groups B and D. Although this study has limitation due to the limited number of pigs (2 pigs per a group), the preliminary data in this study provided the protective potential of SL administration of bacteria-expressed pandemic H1N1 influenza vaccine in pigs. There should be additional animal studies about effective adjuvant system and vaccine types for the use of SL influenza vaccination.
- Sublingual Administration of Bacteria-Expressed Influenza Virus Hemagglutinin 1 (HA1) Induces Protection against Infection with 2009 Pandemic H1N1 Influenza Virus
-
Byoung-Shik Shim , Jung-ah Choi , Ho-Hyun Song , Sung-Moo Park , In Su Cheon , Ji-Eun Jang , Sun Je Woo , Chung Hwan Cho , Min-Suk Song , Hyemi Kim , Kyung Joo Song , Jae Myun Lee , Suhng Wook Kim , Dae Sub Song , Young Ki Choi , Jae-Ouk Kim , Huan Huu Nguyen , Dong Wook Kim , Young Yil Bahk , Cheol-Heui Yun , Man Ki Song
-
J. Microbiol. 2013;51(1):130-135. Published online March 2, 2013
-
DOI: https://doi.org/10.1007/s12275-013-2399-z
-
-
7
View
-
0
Download
-
11
Citations
-
Abstract
- Influenza viruses are respiratory pathogens that continue to pose a significantly high risk of morbidity and mortality of humans worldwide. Vaccination is one of the most effective strategies for minimizing damages by influenza outbreaks. In addition, rapid development and production of efficient vaccine with convenient administration is required in case of influenza pandemic. In this study, we generated recombinant influenza virus hemagglutinin protein 1 (sHA1) of 2009 pandemic influenza virus as a vaccine candidate using a wellestablished bacterial expression system and administered it into mice via sublingual (s.l.) route. We found that s.l. immunization with the recombinant sHA1 plus cholera toxin (CT) induced mucosal antibodies as well as systemic antibodies including neutralizing Abs and provided complete protection against infection with pandemic influenza virus A/CA/04/09 (H1N1) in mice. Indeed, the protection efficacy was comparable with that induced by intramuscular (i.m.) immunization route utilized as general administration route of influenza vaccine. These results suggest that s.l. vaccination with the recombinant non-glycosylated HA1 protein offers an alternative strategy to control influenza outbreaks including pandemics.